Jason Mensah, DO
Psychiatry · Beaumont, TXNPI 1619137593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,090 of the $207,660 with a category attached, or 73.2%. 39 manufacturers reported payments, led by AbbVie at 51.5% of the total. Reporting peaked in 2023 at $54,404 and has fallen 55.8% since, to $24,059 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,035 payments — averaging $200.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$107K
- Axsome Therapeutics, Inc.$41K
- Supernus Pharmaceuticals, Inc.$30K
- Idorsia Pharmaceuticals US Inc$10K
- Johnson & Johnson$5K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $13K from 33 others
Across 179 payments — averaging $57,536 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9.7M
- Supernus Pharmaceuticals, Inc.$441K
- Boehringer Ingelheim International GmbH$90K
- AbbVie$50K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
What the payments were for
- Consulting fees$25,80512%
- Speaking & faculty fees$152,09073%
- Travel & lodging$10,3455%
- Food & beverage$18,9759%
- Education$4450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$207,660 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 37 | $459,708 |
| IngrezzaValbenazine Tosylate | 40 | $344,597 |
| VraylarCariprazine Hcl | 117 | $184,577 |
| Invega TrinzaPaliperidone Palmitate | 11 | $127,412 |
| Abilify MaintenaAripiprazole | 34 | $113,354 |
| AuvelityDextromethorphan Hbr/Bupropion | 80 | $73,440 |
| BelsomraSuvorexant | 147 | $62,097 |
| RexultiBrexpiprazole | 27 | $47,892 |
| SpravatoEsketamine Hcl | 39 | $45,577 |
| TrintellixVortioxetine Hydrobromide | 45 | $31,521 |
| Lurasidone Hcl | 92 | $25,810 |
| CaplytaLumateperone Tosylate | 12 | $20,312 |
| VyvanseLisdexamfetamine Dimesylate | 50 | $19,455 |
| Aripiprazole | 297 | $10,537 |
| SavellaMilnacipran Hcl | 11 | $7,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,695 | $459,70837 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,534 | $344,59740 claims |
| AbbVieVraylar, Savella | $106,935 | $192,487128 claims |
| Johnson & JohnsonInvega Trinza, Spravato | $5,419 | $172,98950 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,527 | $161,24661 claims |
| Axsome Therapeutics, Inc.Auvelity | $41,336 | $73,44080 claims |
| MerckBelsomra | $249 | $62,097147 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $684 | $50,97695 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,451 | $20,31212 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $9,522 | $7,84917 claims |
| Eisai Inc.Dayvigo | $49 | $3,65411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Beaumont
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.